Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diethylstilbestrol | 92 | 2018 | 119 | 7.220 |
Why?
|
Prenatal Exposure Delayed Effects | 45 | 2018 | 153 | 4.930 |
Why?
|
Vaginal Neoplasms | 58 | 2018 | 83 | 4.070 |
Why?
|
Uterine Cervical Neoplasms | 50 | 2018 | 275 | 2.970 |
Why?
|
Estrogens, Non-Steroidal | 26 | 2015 | 30 | 2.610 |
Why?
|
Adenocarcinoma, Clear Cell | 10 | 2018 | 62 | 2.300 |
Why?
|
Pregnancy | 95 | 2018 | 2894 | 1.290 |
Why?
|
Adenocarcinoma | 53 | 2015 | 1169 | 1.250 |
Why?
|
Vaginal Smears | 13 | 2016 | 68 | 0.790 |
Why?
|
Carcinogens | 8 | 2006 | 108 | 0.740 |
Why?
|
Abnormalities, Drug-Induced | 7 | 2015 | 20 | 0.660 |
Why?
|
Female | 148 | 2018 | 44532 | 0.580 |
Why?
|
Ovarian Neoplasms | 14 | 2005 | 744 | 0.570 |
Why?
|
Genital Neoplasms, Female | 9 | 2015 | 107 | 0.570 |
Why?
|
Abortion, Spontaneous | 5 | 2015 | 66 | 0.550 |
Why?
|
Abnormalities, Multiple | 1 | 2015 | 232 | 0.480 |
Why?
|
Follow-Up Studies | 30 | 2018 | 3640 | 0.480 |
Why?
|
Adult | 86 | 2018 | 25648 | 0.430 |
Why?
|
Humans | 151 | 2018 | 86643 | 0.410 |
Why?
|
Uterine Cervical Dysplasia | 5 | 2016 | 27 | 0.400 |
Why?
|
Maternal-Fetal Exchange | 23 | 2018 | 76 | 0.380 |
Why?
|
Cervix Uteri | 15 | 2016 | 65 | 0.360 |
Why?
|
Adolescent | 46 | 2018 | 8981 | 0.350 |
Why?
|
Vaginal Diseases | 16 | 1984 | 27 | 0.340 |
Why?
|
Twins | 2 | 2008 | 65 | 0.340 |
Why?
|
Breast Neoplasms | 13 | 2011 | 2903 | 0.340 |
Why?
|
Fetal Blood | 2 | 2001 | 90 | 0.340 |
Why?
|
Carcinoma, Squamous Cell | 9 | 2016 | 1076 | 0.330 |
Why?
|
Delivery, Obstetric | 1 | 2008 | 112 | 0.320 |
Why?
|
United States | 35 | 2018 | 6672 | 0.320 |
Why?
|
Papillomaviridae | 2 | 2001 | 153 | 0.310 |
Why?
|
Menstruation Disturbances | 3 | 2018 | 24 | 0.270 |
Why?
|
Fetus | 12 | 1981 | 226 | 0.260 |
Why?
|
Risk | 19 | 2018 | 674 | 0.260 |
Why?
|
Cohort Studies | 14 | 2017 | 2767 | 0.250 |
Why?
|
Urogenital Abnormalities | 3 | 2015 | 19 | 0.250 |
Why?
|
Papanicolaou Test | 3 | 2016 | 38 | 0.250 |
Why?
|
Endocrine Disruptors | 2 | 2018 | 27 | 0.240 |
Why?
|
Registries | 11 | 2014 | 702 | 0.240 |
Why?
|
Vagina | 17 | 2000 | 161 | 0.230 |
Why?
|
Incidence | 9 | 2017 | 1577 | 0.230 |
Why?
|
Obstetrics | 2 | 1999 | 120 | 0.230 |
Why?
|
Fertility | 2 | 1995 | 115 | 0.230 |
Why?
|
Odds Ratio | 8 | 2009 | 678 | 0.220 |
Why?
|
Maternal Exposure | 3 | 2009 | 57 | 0.220 |
Why?
|
Age Factors | 19 | 2016 | 1851 | 0.210 |
Why?
|
Middle Aged | 28 | 2018 | 25028 | 0.210 |
Why?
|
Risk Factors | 18 | 2015 | 5417 | 0.210 |
Why?
|
Apgar Score | 1 | 2001 | 13 | 0.210 |
Why?
|
Lead Radioisotopes | 3 | 1989 | 6 | 0.200 |
Why?
|
Menopause | 3 | 2006 | 71 | 0.200 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2001 | 39 | 0.200 |
Why?
|
Child | 24 | 2017 | 6927 | 0.200 |
Why?
|
S100 Proteins | 1 | 2001 | 50 | 0.190 |
Why?
|
Time Factors | 15 | 2017 | 5210 | 0.190 |
Why?
|
Gestational Age | 11 | 2009 | 311 | 0.190 |
Why?
|
Infant, Newborn | 9 | 2008 | 2379 | 0.190 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2000 | 40 | 0.180 |
Why?
|
Uterine Neoplasms | 5 | 2005 | 227 | 0.180 |
Why?
|
Young Adult | 5 | 2018 | 5976 | 0.180 |
Why?
|
Pregnancy Complications | 10 | 2011 | 336 | 0.170 |
Why?
|
Infertility, Female | 5 | 2006 | 93 | 0.160 |
Why?
|
Parity | 5 | 2008 | 93 | 0.160 |
Why?
|
Survival Analysis | 3 | 2018 | 1538 | 0.150 |
Why?
|
Menarche | 2 | 1995 | 24 | 0.150 |
Why?
|
Gynecology | 1 | 1999 | 124 | 0.150 |
Why?
|
Brain | 3 | 2001 | 2216 | 0.150 |
Why?
|
Premature Birth | 1 | 2018 | 113 | 0.150 |
Why?
|
National Institutes of Health (U.S.) | 5 | 1994 | 122 | 0.150 |
Why?
|
Receptors, Estrogen | 5 | 1989 | 384 | 0.150 |
Why?
|
Metabolic Diseases | 1 | 1997 | 48 | 0.150 |
Why?
|
Cardiovascular Diseases | 2 | 2014 | 827 | 0.140 |
Why?
|
Menstrual Cycle | 3 | 1994 | 55 | 0.140 |
Why?
|
Drug Prescriptions | 1 | 2017 | 141 | 0.140 |
Why?
|
Uterine Cervical Diseases | 5 | 1983 | 8 | 0.130 |
Why?
|
Birth Weight | 3 | 2006 | 145 | 0.130 |
Why?
|
Obstetric Labor Complications | 1 | 1995 | 34 | 0.130 |
Why?
|
Terminology as Topic | 3 | 1992 | 217 | 0.130 |
Why?
|
Mass Screening | 4 | 2015 | 618 | 0.130 |
Why?
|
Bacterial Infections | 3 | 2001 | 182 | 0.130 |
Why?
|
Surveys and Questionnaires | 11 | 2015 | 2501 | 0.130 |
Why?
|
Fever | 1 | 1995 | 125 | 0.130 |
Why?
|
Mothers | 2 | 2018 | 141 | 0.130 |
Why?
|
Hypersensitivity | 1 | 1996 | 154 | 0.120 |
Why?
|
Tumor Virus Infections | 1 | 1994 | 81 | 0.120 |
Why?
|
Autoimmune Diseases | 1 | 1996 | 241 | 0.120 |
Why?
|
Pregnancy Outcome | 2 | 2008 | 247 | 0.120 |
Why?
|
Cytodiagnosis | 4 | 1982 | 42 | 0.120 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 1989 | 2438 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 7 | 1989 | 1313 | 0.110 |
Why?
|
Medical Records | 2 | 2008 | 119 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2014 | 176 | 0.110 |
Why?
|
Biopsy, Needle | 3 | 1989 | 235 | 0.110 |
Why?
|
Uterus | 5 | 2007 | 215 | 0.110 |
Why?
|
Maternal Age | 3 | 2008 | 44 | 0.110 |
Why?
|
Intelligence | 1 | 1992 | 71 | 0.110 |
Why?
|
Contraception | 1 | 1993 | 88 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 1996 | 865 | 0.100 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1994 | 381 | 0.100 |
Why?
|
Proportional Hazards Models | 6 | 2013 | 859 | 0.100 |
Why?
|
Physical Examination | 2 | 2008 | 149 | 0.100 |
Why?
|
Combined Modality Therapy | 6 | 2014 | 1686 | 0.100 |
Why?
|
History, 20th Century | 3 | 1999 | 312 | 0.100 |
Why?
|
Precancerous Conditions | 5 | 1994 | 196 | 0.100 |
Why?
|
Osteoporosis | 1 | 2013 | 121 | 0.100 |
Why?
|
Surgical Wound Infection | 2 | 1993 | 184 | 0.100 |
Why?
|
Motor Activity | 1 | 2014 | 327 | 0.100 |
Why?
|
Aged | 11 | 2017 | 18415 | 0.100 |
Why?
|
Papillomavirus Infections | 1 | 1994 | 239 | 0.100 |
Why?
|
Pathology, Clinical | 1 | 1991 | 33 | 0.100 |
Why?
|
Breast Diseases | 2 | 1989 | 97 | 0.100 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 1993 | 28 | 0.100 |
Why?
|
Prognosis | 6 | 2001 | 3679 | 0.100 |
Why?
|
Sweden | 2 | 2008 | 40 | 0.100 |
Why?
|
DNA, Neoplasm | 2 | 1983 | 265 | 0.090 |
Why?
|
Infant Mortality | 2 | 2008 | 59 | 0.090 |
Why?
|
Insurance, Liability | 1 | 1990 | 10 | 0.090 |
Why?
|
Vulva | 1 | 1990 | 23 | 0.090 |
Why?
|
Bismuth | 1 | 1989 | 8 | 0.090 |
Why?
|
Vulvar Neoplasms | 1 | 1990 | 20 | 0.090 |
Why?
|
Male | 22 | 2014 | 40965 | 0.090 |
Why?
|
Radioisotopes | 1 | 1989 | 45 | 0.090 |
Why?
|
Doxorubicin | 4 | 1989 | 295 | 0.090 |
Why?
|
Infant, Premature | 3 | 2008 | 290 | 0.090 |
Why?
|
Pelvic Exenteration | 1 | 1989 | 5 | 0.090 |
Why?
|
Case-Control Studies | 4 | 2015 | 1805 | 0.090 |
Why?
|
Infant, Newborn, Diseases | 2 | 2001 | 111 | 0.090 |
Why?
|
Cefuroxime | 1 | 1989 | 3 | 0.090 |
Why?
|
Malpractice | 1 | 1990 | 57 | 0.090 |
Why?
|
Risk Assessment | 1 | 2017 | 2261 | 0.090 |
Why?
|
Premedication | 1 | 1989 | 54 | 0.090 |
Why?
|
Cephalosporins | 1 | 1989 | 24 | 0.090 |
Why?
|
Smoking | 3 | 1992 | 609 | 0.090 |
Why?
|
Publishing | 1 | 1990 | 90 | 0.090 |
Why?
|
Antibodies, Monoclonal | 4 | 1990 | 1376 | 0.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 1 | 1990 | 176 | 0.090 |
Why?
|
Mental Recall | 1 | 1990 | 159 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1994 | 1197 | 0.090 |
Why?
|
Neoplasms | 5 | 2008 | 2898 | 0.090 |
Why?
|
Genital Diseases, Female | 3 | 1981 | 24 | 0.090 |
Why?
|
Breech Presentation | 1 | 2008 | 12 | 0.090 |
Why?
|
Leg | 1 | 1989 | 137 | 0.080 |
Why?
|
Term Birth | 1 | 2008 | 8 | 0.080 |
Why?
|
Peritoneal Neoplasms | 1 | 1990 | 177 | 0.080 |
Why?
|
Reproduction | 2 | 2018 | 195 | 0.080 |
Why?
|
Aortic Aneurysm | 1 | 1989 | 80 | 0.080 |
Why?
|
Carcinoma, Small Cell | 1 | 1989 | 134 | 0.080 |
Why?
|
Neoplasm Staging | 5 | 2000 | 1939 | 0.080 |
Why?
|
Arterial Occlusive Diseases | 1 | 1989 | 107 | 0.080 |
Why?
|
Contraceptives, Oral | 4 | 2001 | 46 | 0.080 |
Why?
|
Mammography | 1 | 2011 | 463 | 0.080 |
Why?
|
Estradiol Congeners | 2 | 2006 | 8 | 0.080 |
Why?
|
Pelvic Inflammatory Disease | 1 | 1988 | 9 | 0.080 |
Why?
|
Behavior | 1 | 2008 | 85 | 0.080 |
Why?
|
Sex Ratio | 1 | 2007 | 22 | 0.080 |
Why?
|
Serpins | 1 | 1987 | 29 | 0.080 |
Why?
|
Gonadal Steroid Hormones | 2 | 1992 | 50 | 0.080 |
Why?
|
Cesarean Section | 1 | 2008 | 137 | 0.080 |
Why?
|
Blood Vessel Prosthesis | 1 | 1989 | 228 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2001 | 105 | 0.080 |
Why?
|
Contraceptives, Oral, Hormonal | 2 | 2000 | 18 | 0.070 |
Why?
|
Mortality | 2 | 2006 | 149 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 1993 | 746 | 0.070 |
Why?
|
Puberty | 1 | 2007 | 59 | 0.070 |
Why?
|
Neoplasm Metastasis | 8 | 1988 | 1056 | 0.070 |
Why?
|
Colposcopy | 3 | 2001 | 14 | 0.070 |
Why?
|
Epithelium | 9 | 1988 | 319 | 0.070 |
Why?
|
Hemoglobins | 1 | 2007 | 179 | 0.070 |
Why?
|
Logistic Models | 3 | 2015 | 1186 | 0.070 |
Why?
|
Carcinoma | 1 | 1989 | 436 | 0.070 |
Why?
|
Lymph Nodes | 1 | 1990 | 533 | 0.070 |
Why?
|
Double-Blind Method | 3 | 1996 | 1823 | 0.070 |
Why?
|
Hysterectomy | 4 | 1993 | 146 | 0.070 |
Why?
|
Biomarkers, Tumor | 1 | 1994 | 1464 | 0.070 |
Why?
|
Hypospadias | 1 | 2005 | 5 | 0.070 |
Why?
|
Antigens, Neoplasm | 1 | 1987 | 325 | 0.070 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 806 | 0.070 |
Why?
|
Urogenital Neoplasms | 2 | 2008 | 23 | 0.060 |
Why?
|
Cisplatin | 4 | 1989 | 612 | 0.060 |
Why?
|
Agranulocytosis | 1 | 1984 | 20 | 0.060 |
Why?
|
Fetal Death | 2 | 2001 | 56 | 0.060 |
Why?
|
Lithium | 1 | 1984 | 59 | 0.060 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 1373 | 0.060 |
Why?
|
Pre-Eclampsia | 1 | 2007 | 246 | 0.060 |
Why?
|
Confidence Intervals | 3 | 2001 | 229 | 0.060 |
Why?
|
Prospective Studies | 6 | 2014 | 4213 | 0.060 |
Why?
|
Nuclear Family | 3 | 2009 | 92 | 0.060 |
Why?
|
Neutropenia | 1 | 1984 | 215 | 0.060 |
Why?
|
Brachytherapy | 2 | 1999 | 119 | 0.060 |
Why?
|
Endometrial Hyperplasia | 1 | 1982 | 8 | 0.060 |
Why?
|
Thrombocytopenia | 1 | 1984 | 183 | 0.060 |
Why?
|
Genitalia, Male | 3 | 1995 | 24 | 0.060 |
Why?
|
Urethral Diseases | 1 | 1982 | 15 | 0.050 |
Why?
|
Electrosurgery | 1 | 2001 | 9 | 0.050 |
Why?
|
Genitalia, Female | 1 | 1981 | 25 | 0.050 |
Why?
|
Cyclophosphamide | 3 | 1989 | 299 | 0.050 |
Why?
|
Peroxidases | 1 | 1981 | 34 | 0.050 |
Why?
|
Chorioamnionitis | 1 | 2001 | 15 | 0.050 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2007 | 567 | 0.050 |
Why?
|
Germany | 2 | 2014 | 72 | 0.050 |
Why?
|
Triage | 1 | 2001 | 108 | 0.050 |
Why?
|
Evaluation Studies as Topic | 3 | 1990 | 274 | 0.050 |
Why?
|
Sex Factors | 3 | 2014 | 1054 | 0.050 |
Why?
|
Amniotic Fluid | 2 | 1979 | 30 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 2 | 1999 | 1961 | 0.050 |
Why?
|
Retrospective Studies | 8 | 2008 | 8489 | 0.050 |
Why?
|
Causality | 1 | 2000 | 81 | 0.050 |
Why?
|
Coitus | 1 | 1979 | 20 | 0.050 |
Why?
|
Fetal Diseases | 1 | 1979 | 81 | 0.040 |
Why?
|
Regression Analysis | 3 | 2007 | 596 | 0.040 |
Why?
|
Triazenes | 1 | 1979 | 1 | 0.040 |
Why?
|
Carcinoma in Situ | 3 | 1994 | 53 | 0.040 |
Why?
|
Hormone Replacement Therapy | 1 | 2000 | 77 | 0.040 |
Why?
|
Vincristine | 1 | 1979 | 111 | 0.040 |
Why?
|
Menstruation | 4 | 1981 | 30 | 0.040 |
Why?
|
Probability | 2 | 2001 | 355 | 0.040 |
Why?
|
Uterine Hemorrhage | 2 | 1976 | 19 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2018 | 70 | 0.040 |
Why?
|
Cell Line | 3 | 1989 | 2468 | 0.040 |
Why?
|
Leiomyosarcoma | 1 | 1979 | 40 | 0.040 |
Why?
|
Dacarbazine | 1 | 1979 | 102 | 0.040 |
Why?
|
Physicians, Women | 1 | 1999 | 53 | 0.040 |
Why?
|
Ultrasonography | 1 | 2001 | 695 | 0.040 |
Why?
|
Child, Preschool | 5 | 2008 | 3612 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2014 | 6509 | 0.040 |
Why?
|
Terminal Care | 1 | 1999 | 130 | 0.040 |
Why?
|
Metaplasia | 4 | 1979 | 37 | 0.040 |
Why?
|
Alcohol Drinking | 1 | 2000 | 267 | 0.040 |
Why?
|
Endometrial Neoplasms | 1 | 2000 | 193 | 0.040 |
Why?
|
Endometrium | 2 | 1989 | 48 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2001 | 1991 | 0.040 |
Why?
|
Progesterone | 2 | 1974 | 110 | 0.040 |
Why?
|
Sex Chromatin | 1 | 1976 | 4 | 0.040 |
Why?
|
Sex Determination Analysis | 1 | 1976 | 18 | 0.040 |
Why?
|
Remission Induction | 2 | 2007 | 722 | 0.040 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1997 | 493 | 0.040 |
Why?
|
Estrogens | 2 | 1974 | 200 | 0.030 |
Why?
|
Lymphatic Metastasis | 4 | 1989 | 486 | 0.030 |
Why?
|
Analgesia, Epidural | 1 | 1995 | 38 | 0.030 |
Why?
|
Altretamine | 2 | 1986 | 4 | 0.030 |
Why?
|
Infertility, Male | 1 | 1995 | 24 | 0.030 |
Why?
|
Sweating | 1 | 1995 | 1 | 0.030 |
Why?
|
Climacteric | 1 | 1995 | 4 | 0.030 |
Why?
|
Societies, Medical | 1 | 1999 | 572 | 0.030 |
Why?
|
Reoperation | 2 | 1989 | 597 | 0.030 |
Why?
|
Radiation Effects | 1 | 1974 | 28 | 0.030 |
Why?
|
Cell Nucleus | 4 | 1983 | 579 | 0.030 |
Why?
|
Propylthiouracil | 2 | 1965 | 24 | 0.030 |
Why?
|
Primary Ovarian Insufficiency | 1 | 1995 | 20 | 0.030 |
Why?
|
Testosterone | 3 | 1992 | 271 | 0.030 |
Why?
|
Austria | 1 | 2014 | 19 | 0.030 |
Why?
|
Hyperthyroidism | 2 | 1965 | 75 | 0.030 |
Why?
|
Age of Onset | 1 | 1995 | 310 | 0.030 |
Why?
|
Disorders of Sex Development | 1 | 1973 | 18 | 0.030 |
Why?
|
Ovariectomy | 1 | 1994 | 81 | 0.030 |
Why?
|
Cleft Palate | 1 | 1973 | 25 | 0.030 |
Why?
|
DNA, Viral | 1 | 1994 | 265 | 0.030 |
Why?
|
Prevalence | 2 | 1994 | 1239 | 0.030 |
Why?
|
Attitude to Health | 1 | 2015 | 220 | 0.030 |
Why?
|
Embolization, Therapeutic | 1 | 1976 | 238 | 0.030 |
Why?
|
Hormones | 1 | 1973 | 141 | 0.030 |
Why?
|
Abdomen | 1 | 1993 | 122 | 0.030 |
Why?
|
Family | 1 | 1994 | 311 | 0.030 |
Why?
|
Follicle Stimulating Hormone | 2 | 1992 | 147 | 0.030 |
Why?
|
Continuity of Patient Care | 1 | 1994 | 169 | 0.030 |
Why?
|
Aptitude | 1 | 1992 | 10 | 0.030 |
Why?
|
Population Surveillance | 1 | 2014 | 219 | 0.030 |
Why?
|
Luteinizing Hormone | 2 | 1992 | 167 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2015 | 567 | 0.030 |
Why?
|
DNA Probes, HPV | 1 | 1992 | 3 | 0.030 |
Why?
|
Sexual Behavior | 1 | 1995 | 302 | 0.030 |
Why?
|
Male Urogenital Diseases | 1 | 1992 | 9 | 0.030 |
Why?
|
Female Urogenital Diseases | 1 | 1992 | 9 | 0.030 |
Why?
|
Semen | 1 | 1992 | 13 | 0.030 |
Why?
|
Menopause, Premature | 1 | 2011 | 3 | 0.030 |
Why?
|
Stillbirth | 1 | 2011 | 9 | 0.030 |
Why?
|
Testicular Neoplasms | 2 | 2001 | 105 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 1992 | 153 | 0.030 |
Why?
|
Immunoenzyme Techniques | 2 | 1989 | 303 | 0.020 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 378 | 0.020 |
Why?
|
Educational Status | 2 | 2006 | 188 | 0.020 |
Why?
|
Alpha Particles | 1 | 1990 | 4 | 0.020 |
Why?
|
Beta Particles | 1 | 1990 | 5 | 0.020 |
Why?
|
Uterine Cervical Erosion | 3 | 1975 | 3 | 0.020 |
Why?
|
Mesonephroma | 1 | 1970 | 5 | 0.020 |
Why?
|
Health Behavior | 1 | 2011 | 183 | 0.020 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 4 | 0.020 |
Why?
|
Pregnancy, Ectopic | 2 | 2000 | 36 | 0.020 |
Why?
|
Energy Transfer | 1 | 1989 | 25 | 0.020 |
Why?
|
Biopsy | 5 | 1983 | 1163 | 0.020 |
Why?
|
Endometriosis | 1 | 1970 | 58 | 0.020 |
Why?
|
Nipples | 1 | 1989 | 37 | 0.020 |
Why?
|
Cryptorchidism | 1 | 2009 | 11 | 0.020 |
Why?
|
Internship and Residency | 1 | 1999 | 1004 | 0.020 |
Why?
|
Radiation Dosage | 1 | 1990 | 227 | 0.020 |
Why?
|
Vinblastine | 1 | 1989 | 108 | 0.020 |
Why?
|
Carcinoma, Ehrlich Tumor | 1 | 1989 | 7 | 0.020 |
Why?
|
Bioprosthesis | 1 | 1989 | 36 | 0.020 |
Why?
|
Saphenous Vein | 1 | 1989 | 61 | 0.020 |
Why?
|
Bleomycin | 1 | 1989 | 98 | 0.020 |
Why?
|
Injections, Intraperitoneal | 1 | 1989 | 102 | 0.020 |
Why?
|
Etoposide | 1 | 1989 | 196 | 0.020 |
Why?
|
Myometrium | 1 | 1989 | 46 | 0.020 |
Why?
|
Histocytochemistry | 3 | 1985 | 130 | 0.020 |
Why?
|
Radiation Injuries | 1 | 1990 | 155 | 0.020 |
Why?
|
Administration, Intravaginal | 1 | 2008 | 7 | 0.020 |
Why?
|
Hysterosalpingography | 1 | 1988 | 7 | 0.020 |
Why?
|
Carrier Proteins | 3 | 1989 | 673 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 1989 | 1041 | 0.020 |
Why?
|
Steroids | 1 | 1989 | 177 | 0.020 |
Why?
|
Antigens, Tumor-Associated, Carbohydrate | 1 | 1987 | 11 | 0.020 |
Why?
|
Cognition | 1 | 1992 | 570 | 0.020 |
Why?
|
Carcinoembryonic Antigen | 1 | 1987 | 41 | 0.020 |
Why?
|
Radiography | 1 | 1989 | 813 | 0.020 |
Why?
|
Ischemia | 1 | 1989 | 243 | 0.020 |
Why?
|
Preoperative Care | 1 | 1990 | 397 | 0.020 |
Why?
|
Cocarcinogenesis | 1 | 1987 | 12 | 0.020 |
Why?
|
Cell Survival | 1 | 1989 | 969 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2009 | 223 | 0.020 |
Why?
|
Epilepsies, Myoclonic | 1 | 1967 | 13 | 0.020 |
Why?
|
Patient Compliance | 1 | 2008 | 227 | 0.020 |
Why?
|
Radiotherapy, High-Energy | 1 | 1986 | 49 | 0.020 |
Why?
|
Health Surveys | 1 | 2007 | 239 | 0.020 |
Why?
|
Massachusetts | 1 | 1986 | 33 | 0.020 |
Why?
|
Cytosol | 2 | 1989 | 189 | 0.020 |
Why?
|
Cytoplasm | 3 | 1976 | 281 | 0.020 |
Why?
|
Fluorouracil | 1 | 1988 | 556 | 0.020 |
Why?
|
United Kingdom | 1 | 2006 | 164 | 0.020 |
Why?
|
Leukemia | 1 | 2008 | 320 | 0.020 |
Why?
|
Melphalan | 1 | 1986 | 98 | 0.020 |
Why?
|
Bacteria | 1 | 1989 | 447 | 0.020 |
Why?
|
Animals | 6 | 1989 | 26582 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 1988 | 454 | 0.020 |
Why?
|
Ovarian Cysts | 1 | 2005 | 17 | 0.020 |
Why?
|
Cause of Death | 1 | 2006 | 277 | 0.020 |
Why?
|
Statistics as Topic | 1 | 1986 | 238 | 0.020 |
Why?
|
Seasons | 1 | 1986 | 223 | 0.020 |
Why?
|
Colony-Stimulating Factors | 1 | 1984 | 14 | 0.020 |
Why?
|
Lithium Carbonate | 1 | 1984 | 8 | 0.020 |
Why?
|
Practice Patterns, Physicians' | 1 | 1990 | 582 | 0.020 |
Why?
|
Thyroid Gland | 1 | 1965 | 270 | 0.010 |
Why?
|
Antithyroid Agents | 1 | 1963 | 20 | 0.010 |
Why?
|
Polyploidy | 1 | 1983 | 17 | 0.010 |
Why?
|
Thyroid Hormones | 1 | 1965 | 321 | 0.010 |
Why?
|
Reproductive History | 1 | 2002 | 8 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2006 | 1019 | 0.010 |
Why?
|
Electroencephalography | 1 | 1967 | 709 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2008 | 610 | 0.010 |
Why?
|
Prolapse | 1 | 1982 | 10 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2006 | 479 | 0.010 |
Why?
|
Stem Cells | 1 | 1984 | 351 | 0.010 |
Why?
|
Spermatozoa | 1 | 1981 | 62 | 0.010 |
Why?
|
Hyperplasia | 2 | 1979 | 148 | 0.010 |
Why?
|
Culture Techniques | 1 | 2001 | 91 | 0.010 |
Why?
|
Pelvic Neoplasms | 2 | 1979 | 45 | 0.010 |
Why?
|
Gram-Negative Bacteria | 1 | 2001 | 35 | 0.010 |
Why?
|
Gram-Positive Bacteria | 1 | 2001 | 18 | 0.010 |
Why?
|
History, 16th Century | 1 | 2001 | 9 | 0.010 |
Why?
|
History, 17th Century | 1 | 2001 | 12 | 0.010 |
Why?
|
Cell Cycle | 1 | 1983 | 502 | 0.010 |
Why?
|
Leiomyoma | 1 | 2005 | 191 | 0.010 |
Why?
|
Estrogen Replacement Therapy | 1 | 2001 | 45 | 0.010 |
Why?
|
Demography | 1 | 2001 | 177 | 0.010 |
Why?
|
Rabbits | 1 | 1981 | 636 | 0.010 |
Why?
|
Obstetric Labor, Premature | 1 | 2000 | 58 | 0.010 |
Why?
|
Pregnancy, Multiple | 1 | 1980 | 37 | 0.010 |
Why?
|
Fetal Distress | 1 | 1979 | 7 | 0.010 |
Why?
|
Reference Values | 1 | 2001 | 674 | 0.010 |
Why?
|
Epidemiologic Methods | 1 | 1979 | 59 | 0.010 |
Why?
|
Adenoma | 1 | 1981 | 235 | 0.010 |
Why?
|
Remission, Spontaneous | 1 | 1979 | 53 | 0.010 |
Why?
|
Pregnancy Trimester, Second | 1 | 1978 | 66 | 0.010 |
Why?
|
Pregnancy Trimester, First | 1 | 1978 | 63 | 0.010 |
Why?
|
Mosaicism | 1 | 1978 | 67 | 0.010 |
Why?
|
Mice | 2 | 1989 | 11352 | 0.010 |
Why?
|
Placenta | 1 | 1979 | 175 | 0.010 |
Why?
|
Neutrophils | 1 | 1979 | 307 | 0.010 |
Why?
|
DNA | 1 | 1983 | 1294 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1999 | 292 | 0.010 |
Why?
|
Research Design | 2 | 1978 | 594 | 0.010 |
Why?
|
Comorbidity | 1 | 2001 | 943 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 1983 | 1565 | 0.010 |
Why?
|
Aging | 1 | 1981 | 691 | 0.010 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 1976 | 3 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 1979 | 894 | 0.010 |
Why?
|
Haplorhini | 1 | 1976 | 81 | 0.010 |
Why?
|
Angiography | 1 | 1976 | 208 | 0.010 |
Why?
|
Mucous Membrane | 1 | 1975 | 83 | 0.010 |
Why?
|
Social Class | 1 | 1975 | 128 | 0.010 |
Why?
|
Suppositories | 1 | 1974 | 3 | 0.010 |
Why?
|
X-Rays | 1 | 1974 | 130 | 0.010 |
Why?
|
Ethisterone | 1 | 1973 | 1 | 0.010 |
Why?
|
Methandrostenolone | 1 | 1973 | 1 | 0.010 |
Why?
|
Methyltestosterone | 1 | 1973 | 1 | 0.010 |
Why?
|
Mestranol | 1 | 1973 | 4 | 0.010 |
Why?
|
Medroxyprogesterone | 1 | 1973 | 6 | 0.010 |
Why?
|
Tinidazole | 1 | 1993 | 1 | 0.010 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 1973 | 16 | 0.010 |
Why?
|
Norethindrone | 1 | 1973 | 12 | 0.010 |
Why?
|
Ethinyl Estradiol | 1 | 1973 | 16 | 0.010 |
Why?
|
Cefazolin | 1 | 1993 | 7 | 0.010 |
Why?
|
Ovarian Diseases | 1 | 1973 | 32 | 0.010 |
Why?
|
Virus Diseases | 1 | 1974 | 97 | 0.010 |
Why?
|
Metronidazole | 1 | 1993 | 26 | 0.010 |
Why?
|
Glycogen | 1 | 1974 | 59 | 0.010 |
Why?
|
Staining and Labeling | 1 | 1974 | 165 | 0.010 |
Why?
|
Adrenocorticotropic Hormone | 1 | 1973 | 131 | 0.010 |
Why?
|
Macaca mulatta | 1 | 1976 | 459 | 0.010 |
Why?
|
Chicago | 1 | 1978 | 1379 | 0.010 |
Why?
|
Bone and Bones | 1 | 1973 | 265 | 0.010 |
Why?
|
Adrenal Cortex Hormones | 1 | 1973 | 263 | 0.010 |
Why?
|
Parents | 1 | 1975 | 272 | 0.010 |
Why?
|
New York | 1 | 1971 | 69 | 0.010 |
Why?
|
Abortion, Threatened | 1 | 1971 | 1 | 0.010 |
Why?
|
Polycystic Ovary Syndrome | 1 | 1973 | 203 | 0.010 |
Why?
|
Europe | 1 | 1971 | 309 | 0.010 |
Why?
|
Rats | 2 | 1989 | 3990 | 0.010 |
Why?
|
Breast Feeding | 1 | 1971 | 91 | 0.010 |
Why?
|
Epithelial Cells | 1 | 1974 | 669 | 0.010 |
Why?
|
Charcoal | 1 | 1989 | 13 | 0.010 |
Why?
|
Dextrans | 1 | 1989 | 77 | 0.010 |
Why?
|
Rats, Inbred Strains | 1 | 1989 | 312 | 0.010 |
Why?
|
Lung Neoplasms | 2 | 1979 | 2262 | 0.010 |
Why?
|
Epilepsy, Absence | 1 | 1967 | 8 | 0.000 |
Why?
|
Epilepsy, Tonic-Clonic | 1 | 1967 | 8 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1989 | 1047 | 0.000 |
Why?
|
Electromyography | 1 | 1967 | 183 | 0.000 |
Why?
|
Scintillation Counting | 1 | 1985 | 5 | 0.000 |
Why?
|
Centrifugation, Density Gradient | 1 | 1985 | 112 | 0.000 |
Why?
|
Methods | 1 | 1985 | 152 | 0.000 |
Why?
|
Chromatography, Gel | 1 | 1985 | 103 | 0.000 |
Why?
|
Evoked Potentials | 1 | 1967 | 190 | 0.000 |
Why?
|
Spinal Cord | 1 | 1967 | 249 | 0.000 |
Why?
|
Ovulation | 1 | 1984 | 68 | 0.000 |
Why?
|
Microscopy, Electron | 1 | 1985 | 503 | 0.000 |
Why?
|
Neural Pathways | 1 | 1967 | 308 | 0.000 |
Why?
|
Pedigree | 1 | 1967 | 966 | 0.000 |
Why?
|
Thyroidectomy | 1 | 1965 | 170 | 0.000 |
Why?
|
Tamoxifen | 1 | 1985 | 168 | 0.000 |
Why?
|
Photometry | 1 | 1983 | 14 | 0.000 |
Why?
|
Data Display | 1 | 1983 | 24 | 0.000 |
Why?
|
Ploidies | 1 | 1983 | 40 | 0.000 |
Why?
|
Computers | 1 | 1983 | 112 | 0.000 |
Why?
|
Quality Control | 1 | 1983 | 117 | 0.000 |
Why?
|
Immunoglobulin G | 1 | 1985 | 456 | 0.000 |
Why?
|
Ectoderm | 1 | 1982 | 29 | 0.000 |
Why?
|
Phenotype | 1 | 1967 | 2378 | 0.000 |
Why?
|
Cell Nucleolus | 1 | 1974 | 23 | 0.000 |
Why?
|
Ascitic Fluid | 1 | 1974 | 37 | 0.000 |
Why?
|
17-Hydroxycorticosteroids | 1 | 1973 | 6 | 0.000 |
Why?
|
17-Ketosteroids | 1 | 1973 | 13 | 0.000 |
Why?
|
Androstenedione | 1 | 1973 | 29 | 0.000 |
Why?
|
Metabolic Clearance Rate | 1 | 1973 | 121 | 0.000 |
Why?
|
Hirsutism | 1 | 1973 | 61 | 0.000 |
Why?
|
Diabetes Complications | 1 | 1973 | 207 | 0.000 |
Why?
|
Dexamethasone | 1 | 1973 | 326 | 0.000 |
Why?
|